Response Genetics, Inc
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael A Metzger. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael A Metzger has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SNDX / Syndax Pharmaceuticals, Inc. Chief Executive Officer, Director 298,661
US:CTIC / CTI BioPharma Corp Director 0
US:RGDO / President & CEO, Director 837,531
US:RGDX / Director 20,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael A Metzger. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases RGDXQ / Response Genetics, Inc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RGDXQ / Response Genetics, Inc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-02-02 RGDX Metzger Michael A 1,000 1.5000 1,000 1.5000 1,500 12

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RGDXQ / Response Genetics, Inc Insider Trades
Insider Sales RGDXQ / Response Genetics, Inc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RGDXQ / Response Genetics, Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RGDXQ / Response Genetics, Inc Insider Trades
Insider Purchases SNDX / Syndax Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RGDXQ / Response Genetics, Inc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insider Sales SNDX / Syndax Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RGDXQ / Response Genetics, Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-07-16 SNDX Metzger Michael A 7,534 9.2850 7,534 9.2850 69,953 0 9.2500 -264 -0.38
2025-02-10 SNDX Metzger Michael A 13,288 15.5040 13,288 15.5040 206,017

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael A Metzger as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-08 2025-09-08 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -157,307 298,661 -34.50 16.41 -2,582,021 4,902,192
2025-09-08 2025-09-08 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 157,307 455,968 52.67 10.90 1,714,646 4,970,051
2025-07-18 2025-07-16 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale -7,534 298,661 -2.46 9.28 -69,953 2,773,067
2025-03-17 2025-03-14 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 6,074 306,195 2.02 7.20 43,733 2,204,604
2025-03-06 2025-03-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -7,814 300,121 -2.54 15.05 -117,564 4,515,410
2025-03-06 2025-03-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 7,814 307,935 2.60 7.20 56,261 2,217,132
2025-02-12 2025-02-10 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale -13,288 300,121 -4.24 15.50 -206,017 4,653,076
2025-02-07 2025-02-05 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 89,000 313,409 39.66
2025-02-07 2025-02-05 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 60,500 224,409 36.91
2024-02-09 2024-02-07 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 39,000 163,909 31.22
2024-02-09 2024-02-07 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 107,250 124,909 607.34
2023-02-08 2023-02-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -5,959 17,659 -25.23 27.64 -164,697 488,067
2023-02-08 2023-02-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 5,959 23,618 33.74 6.38 38,018 150,683
2022-11-10 2022-11-08 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -4,500 0 -100.00 5.70 -25,660
2022-11-10 2022-11-08 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -36,942 4,500 -89.14 5.65 -208,578 25,407
2022-11-10 2022-11-08 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -50,058 41,442 -54.71 5.53 -276,781 229,141
2022-11-10 2022-11-08 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 63,000 91,500 221.05 1.00 63,000 91,500
2022-11-10 2022-11-08 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 28,500 28,500 0.84 23,971 23,971
2022-10-07 2022-10-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -16,231 17,659 -47.89 25.29 -410,508 446,624
2022-10-07 2022-10-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 16,231 33,890 91.91 8.77 142,346 297,215
2022-10-04 2022-10-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -1,280 17,659 -6.76 25.02 -32,026 441,839
2022-10-04 2022-10-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 1,280 18,939 7.25 8.77 11,226 166,095
2022-10-04 2022-10-03 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -2,883 17,659 -14.03 25.01 -72,107 441,669
2022-10-04 2022-10-03 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 2,883 20,542 16.33 8.77 25,284 180,153
2022-10-04 2022-09-30 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -29,606 17,659 -62.64 25.02 -740,757 441,837
2022-10-04 2022-09-30 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 29,606 47,265 167.65 8.77 259,645 414,514
2022-07-27 2022-07-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -11,838 17,659 -40.13 21.06 -249,254 371,817
2022-07-27 2022-07-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 11,838 29,497 67.04 6.38 75,526 188,191
2022-07-27 2022-07-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -19,764 17,659 -52.81 21.06 -416,139 371,817
2022-07-27 2022-07-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 19,764 37,423 111.92 6.38 126,094 238,759
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -1,100 0 -100.00 6.55 -7,205
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -400 1,100 -26.67 6.54 -2,616 7,194
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -400 1,500 -21.05 6.53 -2,612 9,795
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -3,321 1,900 -63.61 6.52 -21,653 12,388
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -5,900 5,221 -53.05 6.51 -38,409 33,989
2022-07-11 2022-07-07 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -9,000 11,121 -44.73 6.50 -58,500 72,286
2022-07-08 2022-07-07 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -100 17,659 -0.56 21.00 -2,100 370,839
2022-07-08 2022-07-07 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 100 17,759 0.57 6.38 638 113,302
2022-07-08 2022-07-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -15,009 17,659 -45.94 21.07 -316,307 372,155
2022-07-08 2022-07-06 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 15,009 32,668 84.99 6.38 95,757 208,422
2022-07-07 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -3,331 20,121 -14.20 6.23 -20,737 125,263
2022-07-07 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,506 23,452 -53.98 6.14 -168,895 144,002
2022-07-07 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -51,963 50,958 -50.49 6.05 -314,439 308,357
2022-07-07 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -8,700 102,921 -7.79 5.98 -51,996 615,118
2022-07-07 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 91,500 111,621 454.75 0.84 76,961 93,884
2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 80,000 80,000
2022-02-03 2022-02-02 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
A - Award 325,000 325,000 15.79 5,131,750 5,131,750
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -16,000 0 -100.00
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -45,000 0 -100.00
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -45,000 17,659 -71.82 20.29 -912,960 358,266
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 45,000 62,659 254.83 8.77 394,650 549,519
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -16,000 17,659 -47.54 20.29 -324,608 358,266
2021-12-20 2021-12-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 16,000 33,659 90.61 6.38 102,080 214,744
2021-12-20 2021-12-17 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -1,676 0 -100.00
2021-12-20 2021-12-17 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -1,676 17,659 -8.67 19.02 -31,877 335,871
2021-12-20 2021-12-17 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 1,676 19,335 9.49 6.38 10,693 123,357
2021-12-20 2021-12-16 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -22,715 0 -100.00
2021-12-20 2021-12-16 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -22,715 17,659 -56.26 19.08 -433,400 336,932
2021-12-20 2021-12-16 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 22,715 40,374 128.63 6.38 144,922 257,586
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -34,564 0 -100.00
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -2,045 0 -100.00
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -34,564 17,659 -66.19 19.05 -658,555 336,460
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 34,564 52,223 195.73 6.38 220,518 333,183
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -2,045 17,659 -10.38 19.05 -38,964 336,460
2021-12-15 2021-12-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 2,045 19,704 11.58 7.20 14,724 141,869
2021-10-27 2021-10-26 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -16,296 0 -100.00
2021-10-27 2021-10-26 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -16,296 17,659 -47.99 19.20 -312,825 338,989
2021-10-27 2021-10-26 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 16,296 33,955 92.28 7.20 117,331 244,476
2021-10-27 2021-10-25 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -44,704 0 -100.00
2021-10-27 2021-10-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -44,704 17,659 -71.68 19.13 -855,335 337,875
2021-10-27 2021-10-25 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 44,704 62,363 253.15 7.20 321,869 449,014
2021-09-28 2021-09-27 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -24,437 0 -100.00
2021-09-28 2021-09-27 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -24,437 17,659 -58.05 19.51 -476,832 344,575
2021-09-28 2021-09-27 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 24,437 42,096 138.38 7.20 175,946 303,091
2021-09-22 2021-09-22 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -300 0 -100.00
2021-09-22 2021-09-22 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -300 17,659 -1.67 19.02 -5,706 335,874
2021-09-22 2021-09-22 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 300 17,959 1.70 7.20 2,160 129,305
2021-09-22 2021-09-21 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -4,808 0 -100.00
2021-09-22 2021-09-21 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -4,808 17,659 -21.40 19.16 -92,108 338,299
2021-09-22 2021-09-21 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 4,808 22,467 27.23 7.20 34,618 161,762
2021-09-22 2021-09-20 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -31,455 0 -100.00
2021-09-22 2021-09-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -31,455 17,659 -64.04 19.24 -605,046 339,676
2021-09-22 2021-09-20 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 31,455 49,114 178.12 7.20 226,476 353,621
2021-09-15 2021-09-14 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -44,349 0 -100.00
2021-09-15 2021-09-14 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -44,349 17,659 -71.52 19.15 -849,394 338,214
2021-09-15 2021-09-14 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 44,349 62,008 251.14 7.20 319,313 446,458
2021-09-15 2021-09-13 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -16,651 0 -100.00
2021-09-15 2021-09-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -16,651 17,659 -48.53 19.02 -316,639 335,807
2021-09-15 2021-09-13 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 16,651 34,310 94.29 7.20 119,887 247,032
2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 80,000 80,000
2021-02-05 2021-02-03 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 160,000 160,000
2021-02-03 2021-02-01 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -15,000 0 -100.00
2021-02-03 2021-02-01 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -15,000 17,659 -45.93 20.19 -302,799 356,475
2021-02-03 2021-02-01 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 15,000 32,659 84.94 7.20 108,000 235,145
2020-12-03 2020-12-01 4 SNDX Syndax Pharmaceuticals Inc
Employee Stock Option (right to buy)
M - Exercise -15,000 0 -100.00
2020-12-03 2020-12-01 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -15,000 17,659 -45.93 22.97 -344,512 405,583
2020-12-03 2020-12-01 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 15,000 32,659 84.94 7.20 108,000 235,145
2020-11-06 2020-11-04 4 SNDX Syndax Pharmaceuticals Inc
Stock Options (Right to buy)
M - Exercise -100,000 0 -100.00
2020-11-06 2020-11-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
S - Sale X -100,000 17,659 -84.99 20.31 -2,031,410 358,727
2020-11-06 2020-11-04 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
M - Exercise 100,000 117,659 566.28 7.20 720,000 847,145
2020-03-13 2020-03-11 4 CTIC CTI BIOPHARMA CORP
Non-qualified Stock Option
A - Award 126,000 126,000
2020-02-14 2020-02-12 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 140,000 140,000
2020-02-14 2020-02-12 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
A - Award 15,000 17,659 564.12
2019-07-08 2019-07-04 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 200,000 200,000
2019-05-20 2019-05-16 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 120,000 120,000
2019-02-08 2019-02-06 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 240,000 240,000
2019-02-08 2019-01-31 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
J - Other 2,659 2,659 4.76 12,657 12,657
2018-05-17 2018-05-17 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 60,000 60,000
2018-03-05 2018-03-01 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 125,000 125,000
2018-01-22 2018-01-20 4 ctic CTI BIOPHARMA CORP
Restricted Stock Unit
M - Exercise -20,121 0 -100.00
2018-01-22 2018-01-20 4 ctic CTI BIOPHARMA CORP
Common Stock
M - Exercise 20,121 20,121
2017-02-27 2017-02-23 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 50,000 50,000
2017-02-08 2017-02-06 4 SNDX Syndax Pharmaceuticals Inc
Stock Option (Right to Buy)
A - Award 95,000 95,000
2017-01-24 2017-01-20 4 CTIC CTI BIOPHARMA CORP
Restricted Stock Units
A - Award 20,121 20,121
2017-01-24 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share
0
2015-02-20 2014-12-03 4/A RGDO Regado Biosciences Inc
Stock Option (right to buy)
A - Award 837,531 837,531
2014-12-05 2014-12-03 4 RGDO Regado Biosciences Inc
Stock Option (right to buy)
A - Award 837,531 837,531
2013-12-20 2013-12-16 4 RGDO Regado Biosciences Inc
Stock Option (right to buy)
A - Award 434,008 434,008
2012-08-01 2012-07-30 4 RGDX RESPONSE GENETICS INC
Stock Option (right to buy)
A - Award 20,000 20,000
2012-02-06 2012-02-02 4 RGDX RESPONSE GENETICS INC
Common Stock, par value $0.01 per share
P - Purchase 1,000 1,000 1.50 1,500 1,500
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)